Cxcr2 antagonists not only to reduce metastasis, tumor growth and improve response to chemotherapy in the xenograft model [18], but suppress inflammation-driven intestinal adenocarcinomas [25] and improve survival in a KRas-driven pancreatic ductal adenocarcinoma model [37]. Here, KRAS is linked to pancreatic ductal adenocarcinoma.